Drug Approval | April 28, 2025
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The company has received the GMP Certification after successful closure of the inspection
The trademark rights for these brands will be transferred to Lupin by March next year.
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Subscribe To Our Newsletter & Stay Updated
